Summer B Gibson1, Diana Abbott1, James M Farnham1, Khanh K Thai1, Hailey McLean1, Karla P Figueroa1, Mark B Bromberg1, Stefan M Pulst1, Lisa Cannon-Albright2. 1. From the Department of Neurology (S.B.G., K.P.F., M.B.B., S.M.P.) and Division of Genetic Epidemiology, Department of Internal Medicine (D.A., J.M.F., K.K.T., L.C.-A.), University of Utah, School of Medicine, Salt Lake City; College of Behavioral and Social Science (H.M.), University of Utah, Salt Lake City; and George E. Wahlen Department of Veterans Affairs Medical Center (L.C.-A.), Salt Lake City, UT. 2. From the Department of Neurology (S.B.G., K.P.F., M.B.B., S.M.P.) and Division of Genetic Epidemiology, Department of Internal Medicine (D.A., J.M.F., K.K.T., L.C.-A.), University of Utah, School of Medicine, Salt Lake City; College of Behavioral and Social Science (H.M.), University of Utah, Salt Lake City; and George E. Wahlen Department of Veterans Affairs Medical Center (L.C.-A.), Salt Lake City, UT. lisa.albright@utah.edu.
Abstract
OBJECTIVE: To estimate the risks for cancer (overall and site-specific) in an amyotrophic lateral sclerosis (ALS) cohort. METHODS: In this observational longitudinal study, ALS and cancer cases were identified in a computerized Utah genealogy database (Utah Population Database) linked to a statewide cancer registry and death certificates. Hazard ratios (HRs) were estimated as the ratio of observed to expected number of cancers. Site-specific rates for cancer were estimated within the Utah Population Database; sex, birth year (5-year range), and birth state (Utah or not) cohorts were used to estimate the expected number of cancers among ALS cases. To account for an overall shortened lifespan, Cox regression was used to include years at risk in estimation of cancer risks for ALS cases. RESULTS: An overall decreased hazard (hazard ratio [HR] 0.80, p = 0.014, 95% confidence interval [CI] 0.66-0.96) was found for cancer of any site in 1,081 deceased patients with ALS. A decreased hazard was found for lung cancer (HR 0.23, p = 0.002, CI 0.05-0.63). An increased hazard was found for salivary (HR 5.27, p = 0.041, 95% CI 1.09-15.40) and testicular (HR 3.82, p = 0.042, 95% CI 1.06-9.62) cancers. A nonsignificant hazard was observed for cutaneous malignant melanoma (HR 1.62, p = 0.12, 95% CI 0.88-2.71) for which increased risk has previously been reported. CONCLUSIONS: Using a unique population database, the overall risk of cancer of any site was found to be significantly reduced in cases with ALS, as was the risk of lung cancer. Significantly increased risk was observed for salivary and testicular cancers.
OBJECTIVE: To estimate the risks for cancer (overall and site-specific) in an amyotrophic lateral sclerosis (ALS) cohort. METHODS: In this observational longitudinal study, ALS and cancer cases were identified in a computerized Utah genealogy database (Utah Population Database) linked to a statewide cancer registry and death certificates. Hazard ratios (HRs) were estimated as the ratio of observed to expected number of cancers. Site-specific rates for cancer were estimated within the Utah Population Database; sex, birth year (5-year range), and birth state (Utah or not) cohorts were used to estimate the expected number of cancers among ALS cases. To account for an overall shortened lifespan, Cox regression was used to include years at risk in estimation of cancer risks for ALS cases. RESULTS: An overall decreased hazard (hazard ratio [HR] 0.80, p = 0.014, 95% confidence interval [CI] 0.66-0.96) was found for cancer of any site in 1,081 deceased patients with ALS. A decreased hazard was found for lung cancer (HR 0.23, p = 0.002, CI 0.05-0.63). An increased hazard was found for salivary (HR 5.27, p = 0.041, 95% CI 1.09-15.40) and testicular (HR 3.82, p = 0.042, 95% CI 1.06-9.62) cancers. A nonsignificant hazard was observed for cutaneous malignant melanoma (HR 1.62, p = 0.12, 95% CI 0.88-2.71) for which increased risk has previously been reported. CONCLUSIONS: Using a unique population database, the overall risk of cancer of any site was found to be significantly reduced in cases with ALS, as was the risk of lung cancer. Significantly increased risk was observed for salivary and testicular cancers.
Authors: Raymond Y Lo; Caroline M Tanner; Stephen K Van Den Eeden; Kathleen B Albers; Amethyst D Leimpeter; Lorene M Nelson Journal: Mov Disord Date: 2010-09-15 Impact factor: 10.338
Authors: Summer B Gibson; Karla P Figueroa; Mark B Bromberg; Stefan-M Pulst; Lisa Cannon-Albright Journal: Neurology Date: 2013-12-04 Impact factor: 9.910
Authors: Jane A Driver; Giancarlo Logroscino; Julie E Buring; J Michael Gaziano; Tobias Kurth Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: Jane A Driver; Alexa Beiser; Rhoda Au; Bernard E Kreger; Greta Lee Splansky; Tobias Kurth; Douglas P Kiel; Kun Ping Lu; Sudha Seshadri; Phillip A Wolf Journal: BMJ Date: 2012-03-12
Authors: Thomas Kuczmarski; Elijah W Stommel; Kristen Riley; Rup Tandan; Vinay Chaudhry; Lora Clawson; Tracie A Caller; Patricia L Henegan; Dominic N Facciponte; Walter G Bradley; Angeline S Andrew Journal: J Neurol Date: 2017-07-15 Impact factor: 4.849
Authors: Heather M Snyder; Tim Ahles; Stuart Calderwood; Maria C Carrillo; Honglei Chen; Chung-Chou H Chang; Suzanne Craft; Philip De Jager; Jane A Driver; Howard Fillit; David Knopman; Michael Lotze; Mary C Tierney; Suzana Petanceska; Andrew Saykin; Sudha Seshadri; Diana Shineman; Mary Ganguli Journal: Alzheimers Dement Date: 2016-12-18 Impact factor: 21.566
Authors: Hari Krishna Raju Sagiraju; Sasa Živković; Anne C VanCott; Huned Patwa; David Gimeno Ruiz de Porras; Megan E Amuan; Mary Jo V Pugh Journal: Mil Med Date: 2020-03-02 Impact factor: 1.437
Authors: Madelyn E McCauley; Jacqueline Gire O'Rourke; Alberto Yáñez; Janet L Markman; Ritchie Ho; Xinchen Wang; Shuang Chen; Deepti Lall; Mengyao Jin; A K M G Muhammad; Shaughn Bell; Jesse Landeros; Viviana Valencia; Matthew Harms; Moshe Arditi; Caroline Jefferies; Robert H Baloh Journal: Nature Date: 2020-08-19 Impact factor: 49.962